Refractory

25 clinical trials · Condition

Record	Firm	Date
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)	Biomea Fusion Inc.	2022-01-24
NK Cell Therapy Recurrent/Refractory Elderly AML (NCT04599452)	The Second Hospital of Shandong University	2020-12-01
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies (NCT03881774)	Henan Cancer Hospital	2019-02-27
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma (NCT03881761)	Henan Cancer Hospital	2019-02-01
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia (NCT03275493)	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd	2017-07-01
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas (NCT03179930)	Memorial Sloan Kettering Cancer Center	2017-06-07
Rhinosinusites Chroniques (NCT02407275)	Institut Hospitalo-Universitaire Méditerranée Infection	2015-02-01
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients (NCT02280993)	Marjolein Spiering	2014-05-01
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients (NCT00752518)	Janssen Pharmaceutical K.K.	2004-05-01

Every clearance here is in the API, with alerts when new ones post.